Volume 1, Issue 8: Role of GLP-1 Receptor Agonists in the Treatment Continuum of Type 2 Diabetes-PODCAST
e-Diabetes Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with diabetes. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 1, Issue 8)
Target Audience
Nurses and health care professionals involved in the care of patients with diabetes.
Learning Objectives
After participating in this activity, the participant will demonstrate the ability to:
- Explain why GLP-1 agonists should be considered early in the treatment of T2DM in obese patients.
- Discuss why GLP-1 agonists may be a better choice than basal insulin in selected obese patients with T2DM.
- Describe why adding GLP-1 agonist to a treatment regimen that already includes basal insulin may be better than adding nutritional insulin in obese patients with T2DM.
Rajesh Garg, MD
Assistant Professor of Medicine
Harvard Medical School
Associate Physician, Division of Endocrinology, Diabetes and Hypertension
Brigham and Women’s Hospital
Boston, Massachusetts
Available Credit
- 0.50 ANCC